Boldenone (also referred to as Equipoise) was developed as a long version of methandienone and patented by Ciba as a synthetic anabolic steroid in 1949. However the result was a steroid with fully different properties, despite the chemical similarity. Boldenone was developed mainly for dystrophy treatment and to increase bone weight and density in osteoporosis.
Boldenone is an injectable long-term steroid that exhibits strong anabolic and moderately androgenic properties. Low androgenic properties enable boldenone for women to use. Virilization occurs rarely, as compared to other steroids. Boldenone is one of the few injectable drugs that can be taken by female athletes almost without risk of side effects.
Boldenone greatly stimulates hematopoiesis. Elevated levels of red blood cells improve oxygen delivery to the muscles. This makes this steroid attractive for track and field athletes.
Athletes taking boldenone often report a slow but high lean muscle growth. All positive effects of the drug become apparent on long cycles (12 weeks or more). Muscles on boldenone cycle will be denser than muscles on testosterone. Boldenone does not retain water in muscles, so their volume after the cycle shall be the same as on cycle. The drug increases the power rate and significantly raises appetite.